The Kynurenine/Tryptophan Ratio and Glioblastoma Patients Treated with Hsppc-96 Vaccine

Alicia Lenzen^1,2,3,4, Lijie Zhai¹, Kristen L Lauing¹, Galina Gritsina¹, Erik Ladomersky¹, Matthew Genet¹, C David James^1,5,9,10, Orin Bloch^1,6,9,10 and Derek A Wainwright^1,7,8,9,10*

¹Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, USA

²Department of Pediatrics, Northwestern University Feinberg School of Medicine, USA

³Division of Hematology, Oncology and Stem Cell Transplantation, Northwestern University Feinberg School of Medicine, USA

⁴Ann & Robert H. Lurie Children’s Hospital of Chicago, Northwestern University Feinberg School of Medicine, USA

⁵Department of Biochemistry and Molecular Genetics, Northwestern University Feinberg School of Medicine, USA

⁶Department of Neurology, Northwestern University Feinberg School of Medicine, USA

⁷Department of Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, USA

⁸Department of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, USA

⁹Brain Tumor Institute, Northwestern University Feinberg School of Medicine, USA

¹⁰Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA

^*Corresponding Author: Derek A Wainwright, Ph.D., Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, 300 East Superior St., Tarry Building, Room 2-703, Chicago, USA, Tel: (312) 503-3161, Fax: (312) 503-3552 Email: